The Journal of Heart and Lung Transplantation
Volume 26, Issue 10 , Pages 1048-1053, October 2007

Donor Cardiac Troponin I Levels Do Not Predict Recipient Survival After Cardiac Transplantation

  • Kiran K. Khush, MD

      Affiliations

    • Division of Cardiology, Department of Medicine, University of California at San Francisco Medical Center, San Francisco, California
    • Corresponding Author InformationReprint requests: Kiran K. Khush, MD, 505 Parnassus Ave, Box 0124, San Francisco, CA 94143. Telephone: 415-476-0626. Fax: 415-476-0424
  • ,
  • Rebecca L. Menza, ACNP, MS

      Affiliations

    • California Transplant Donor Network, Oakland, California.
  • ,
  • Wayne D. Babcock, RN

      Affiliations

    • California Transplant Donor Network, Oakland, California.
  • ,
  • Jonathan G. Zaroff, MD

      Affiliations

    • Division of Cardiology, Department of Medicine, University of California at San Francisco Medical Center, San Francisco, California

Received 9 July 2006; received in revised form 7 January 2007; accepted 15 July 2007.

Background

Serum levels of cardiac troponin I (cTnI) are frequently measured in the evaluation of potential heart donors. However, the utility of cTnI levels for predicting recipient outcomes remains controversial. This study was performed to determine whether donor cardiac cTnI levels exceeding 1.0 μg/liter are associated with adverse recipient outcomes.

Methods

All donors managed by the California Transplant Donor Network between January 2001 and July 2002 with consent for donor evaluation and at least 1 measured cTnI level were included in the study if 1-year recipient mortality data were available. Each study subject was classified as having elevated cTnI if any level exceeded 1.0 μg/liter. Donor variables, recipient risk of 30-day and 1-year mortality, and recipient need for mechanical circulatory support were compared between the 2 groups.

Results

A total of 263 potential donors were evaluated, and 98 had elevated cTnI levels. Of these potential donors, 139 were accepted for transplantation. The cTnI levels were normal in 96 and elevated in 43. Most donors (77%) with elevated cTnI levels had levels of less than 10 μg/liter. Donor cardiopulmonary resuscitation was associated with cTnI elevations. Donors with elevated cTnI levels did not require higher doses of inotropic drugs before transplantation and had similar hemodynamic profiles compared with donors with normal cTnI levels. Although there was a trend towards longer post-transplant hospitalization in recipients of grafts from donors with elevated cTnI levels (17 days vs 15 days, p = 0.044), there was no significant difference in the recipient need for mechanical circulatory support or 30-day and 1-year mortality between the 2 groups.

Conclusions

In this study, a modestly elevated donor cTnI was not associated with a higher risk of recipient mortality or need for post-transplant mechanical circulatory support. A potential donor heart should not be discarded solely because the troponin level is elevated.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1053-2498(07)00539-6

doi:10.1016/j.healun.2007.07.026

The Journal of Heart and Lung Transplantation
Volume 26, Issue 10 , Pages 1048-1053, October 2007